Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells

por Burgess, Brian T., Anderson, Abigail M., McCorkle, J. Robert, Wu, Jianrong, Ueland, Frederick R., Kolesar, Jill M.
Publicado 2020

Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery

por Smith, Christopher G., Davenport, Daniel L., Gorski, Justin, McDowell, Anthony, Burgess, Brian T., Fredericks, Tricia I., Baldwin, Lauren A., Miller, Rachel W., DeSimone, Christopher P., Dietrich, Charles S., Gallion, Holly H., Pavlik, Edward J., van Nagell, John R., Ueland, Frederick R.
Publicado 2019

Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness

por Pavlik, Edward J., Smith, Christopher, Dennis, Taylor S., Harvey, Elizabeth, Huang, Bin, Chen, Quan, West Piecoro, Dava, Burgess, Brian T., McDowell, Anthony, Gorski, Justin, Baldwin, Lauren A., Miller, Rachel W., DeSimone, Christopher P., Dietrich, Charles, Gallion, Holly H., Ueland, Frederick R., van Nagell, John R.
Publicado 2020